DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main »

Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main

Quarter-by-quarter ownership of Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main from 13F filings

Historical chart of DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main investment in Halozyme Therapeutics Inc Note 1.000 8/1

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics Inc Note 1.000 8/1 held by DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics Inc Note 1.000 8/1 by DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main

Quarter filed Position value Share count Share price at filing
2023-12-31 $7.4M 8.0M 0.93
2023-09-30 $7.5M 8.0M 0.93

More positions owned by DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main

Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation Call Option (NVDA)
Amazon (AMZN)
Alphabet Cap Stk Cl A Call Option (GOOGL)
JPMorgan Chase & Co. (JPM)
Meta Platforms Cl A (META)
Linde SHS (LIN)
Eli Lilly & Co. (LLY)
Micron Technology (MU)
UnitedHealth (UNH)
Merck & Co (MRK)
Bank of America Corporation (BAC)
Servicenow (NOW)
Boston Scientific Corporation (BSX)

View all positions for DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main

Top funds holding Halozyme Therapeutics Inc Note 1.000 8/1

M&g Investment Management
Calamos Advisors
Wolverine Asset Management
MacKay Shields
Citadel Advisors
Polar Securities
Millennium Management
Bank Of Montreal
Kohlberg Kravis Roberts & Co
D. E. Shaw & Co
Absolute Investment Advisers
Leucadia National Corporation
SSI Investment Management
CSS
Readystate Asset Management

View all funds holding Halozyme Therapeutics Inc Note 1.000 8/1